Logo image of NXGN

NEXTGEN HEALTHCARE INC (NXGN) Stock Fundamental Analysis

NASDAQ:NXGN - Nasdaq - US65343C1027 - Common Stock - Currency: USD

23.94  +0.03 (+0.13%)

After market: 23.93 -0.01 (-0.04%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NXGN. NXGN was compared to 36 industry peers in the Health Care Technology industry. Both the profitability and the financial health of NXGN get a neutral evaluation. Nothing too spectacular is happening here. NXGN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

NXGN had positive earnings in the past year.
In the past year NXGN has reported a negative cash flow from operations.
Of the past 5 years NXGN 4 years were profitable.
NXGN had a positive operating cash flow in each of the past 5 years.
NXGN Yearly Net Income VS EBIT VS OCF VS FCFNXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

1.2 Ratios

The Return On Assets of NXGN (-0.72%) is better than 78.57% of its industry peers.
Looking at the Return On Equity, with a value of -1.47%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
NXGN's Return On Invested Capital of 0.82% is fine compared to the rest of the industry. NXGN outperforms 78.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NXGN is below the industry average of 6.38%.
Industry RankSector Rank
ROA -0.72%
ROE -1.47%
ROIC 0.82%
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
NXGN Yearly ROA, ROE, ROICNXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2 4 6 8

1.3 Margins

Looking at the Operating Margin, with a value of 1.06%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
In the last couple of years the Operating Margin of NXGN has declined.
The Gross Margin of NXGN (46.40%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NXGN has declined.
Industry RankSector Rank
OM 1.06%
PM (TTM) N/A
GM 46.4%
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
NXGN Yearly Profit, Operating, Gross MarginsNXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NXGN is destroying value.
NXGN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NXGN has been increased compared to 5 years ago.
Compared to 1 year ago, NXGN has a worse debt to assets ratio.
NXGN Yearly Shares OutstandingNXGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
NXGN Yearly Total Debt VS Total AssetsNXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

NXGN has an Altman-Z score of 3.59. This indicates that NXGN is financially healthy and has little risk of bankruptcy at the moment.
NXGN's Altman-Z score of 3.59 is fine compared to the rest of the industry. NXGN outperforms 78.57% of its industry peers.
NXGN has a Debt/Equity ratio of 0.63. This is a neutral value indicating NXGN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.63, NXGN is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Altman-Z 3.59
ROIC/WACC0.08
WACC10.14%
NXGN Yearly LT Debt VS Equity VS FCFNXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.52 indicates that NXGN has no problem at all paying its short term obligations.
NXGN has a Current ratio (2.52) which is in line with its industry peers.
NXGN has a Quick Ratio of 2.52. This indicates that NXGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.52, NXGN perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.52
NXGN Yearly Current Assets VS Current LiabilitesNXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.33% over the past year.
Measured over the past 5 years, NXGN shows a small growth in Earnings Per Share. The EPS has been growing by 6.96% on average per year.
NXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.25%.
Measured over the past years, NXGN shows a small growth in Revenue. The Revenue has been growing by 4.23% on average per year.
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%

3.2 Future

Based on estimates for the next years, NXGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.15% on average per year.
NXGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.76% yearly.
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NXGN Yearly Revenue VS EstimatesNXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NXGN Yearly EPS VS EstimatesNXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 21.38, NXGN is valued on the expensive side.
Based on the Price/Earnings ratio, NXGN is valued cheaper than 92.86% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.28. NXGN is valued slightly cheaper when compared to this.
NXGN is valuated rather expensively with a Price/Forward Earnings ratio of 17.59.
92.86% of the companies in the same industry are more expensive than NXGN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of NXGN to the average of the S&P500 Index (21.76), we can say NXGN is valued inline with the index average.
Industry RankSector Rank
PE 21.38
Fwd PE 17.59
NXGN Price Earnings VS Forward Price EarningsNXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NXGN is valued a bit cheaper than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 34.12
NXGN Per share dataNXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NXGN's earnings are expected to grow with 17.28% in the coming years.
PEG (NY)1.48
PEG (5Y)3.07
EPS Next 2Y17.83%
EPS Next 3Y17.28%

More info and screens

0

5. Dividend

5.1 Amount

NXGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXTGEN HEALTHCARE INC

NASDAQ:NXGN (11/8/2023, 8:00:02 PM)

After market: 23.93 -0.01 (-0.04%)

23.94

+0.03 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)10-24 2023-10-24/amc
Earnings (Next)01-22 2024-01-22/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners31.12%
Ins Owner Change0%
Market Cap1.61B
Analysts50.77
Price Target24.41 (1.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.71
Dividend Growth(5Y)3.39%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.08%
Min EPS beat(2)6.95%
Max EPS beat(2)23.21%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-6.17%
Max EPS beat(4)23.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)0.72%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)2.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.11%
PT rev (3m)16.34%
EPS NQ rev (1m)-2.38%
EPS NQ rev (3m)-0.97%
EPS NY rev (1m)0%
EPS NY rev (3m)0.55%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 21.38
Fwd PE 17.59
P/S 2.31
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 94.94
EV/EBITDA 34.12
EPS(TTM)1.12
EY4.68%
EPS(NY)1.36
Fwd EY5.68%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS10.36
BVpS6.31
TBVpS0.25
PEG (NY)1.48
PEG (5Y)3.07
Profitability
Industry RankSector Rank
ROA -0.72%
ROE -1.47%
ROCE 1.04%
ROIC 0.82%
ROICexc 1.14%
ROICexgc 5.45%
OM 1.06%
PM (TTM) N/A
GM 46.4%
FCFM N/A
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
ROICexc(3y)2.27%
ROICexc(5y)3.46%
ROICexgc(3y)18.71%
ROICexgc(5y)23.54%
ROCE(3y)2.41%
ROCE(5y)3.74%
ROICexcg growth 3Y-50.16%
ROICexcg growth 5Y-31.62%
ROICexc growth 3Y-56.26%
ROICexc growth 5Y-28.38%
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
F-Score2
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Debt/EBITDA 5.98
Cap/Depr 95.52%
Cap/Sales 5.14%
Interest Coverage 1.1
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.52
Quick Ratio 2.52
Altman-Z 3.59
F-Score2
WACC10.14%
ROIC/WACC0.08
Cap/Depr(3y)75.15%
Cap/Depr(5y)68.18%
Cap/Sales(3y)5.17%
Cap/Sales(5y)5.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
EBIT growth 1Y-70.75%
EBIT growth 3Y-55.58%
EBIT growth 5Y-24.47%
EBIT Next Year47.96%
EBIT Next 3Y27.47%
EBIT Next 5Y21.11%
FCF growth 1Y-203.01%
FCF growth 3Y-52.24%
FCF growth 5Y-32.4%
OCF growth 1Y-110.78%
OCF growth 3Y-20.1%
OCF growth 5Y-10.01%